Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Medical Genetics · SHORT Syndrome

Managing SHORT Syndrome: A Specialized Care Plan

At a Glance

SHORT syndrome care is individualized: regular blood-sugar monitoring, nutrition and activity support, and specialist decisions about medicines or growth hormone help manage insulin resistance while eye, dental, and selected heart screenings watch for complications.

Managing SHORT syndrome and related PIK3R1 conditions requires a highly individualized approach. Because these conditions are rare, there is no single “standard” treatment plan; instead, care is built around your specific symptoms and metabolic needs [1][2]. Your care team will likely include specialists in genetics, endocrinology, ophthalmology, and nutrition [3]. Medication decisions belong to a specialist, and several options are considered off-label.

Managing Severe Insulin Resistance

The most critical part of long-term care is monitoring and treating insulin resistance. Because your cells do not respond normally to insulin, the body must work harder to manage sugar [2].

  • Proactive Monitoring: Doctors recommend regular blood tests, including fasting glucose, HbA1c, and sometimes an oral glucose tolerance test (OGTT), especially as children approach puberty, when insulin resistance often worsens [4][5].
  • Medications:
    • Metformin is often the first medication tried. However, its effectiveness in SHORT syndrome is inconsistent; while some patients improve, others may not see better sugar control [2][6]. Metformin is not a guaranteed treatment for every person with isolated insulin resistance.
    • Other Options: Some specialists may use medications like pioglitazone (which helps cells “hear” insulin better) or newer classes like SGLT2 inhibitors (which help the kidneys remove sugar), though evidence for these in SHORT syndrome is currently based on individual case reports [7][8]. These off-label medications carry significant risks: SGLT2 inhibitors can cause genital infections, dehydration, and euglycemic ketoacidosis; pioglitazone has concerns regarding edema, weight gain, fractures, and heart failure.
    • Insulin Therapy: If diabetes develops, insulin may be necessary. In some cases, exceptionally high doses are required because of the underlying signaling defect [9][10]. Risks include weight gain and hypoglycemia.

Addressing Growth and Short Stature

While “Short Stature” is part of the syndrome’s name, treating it is not always straightforward.

  • Growth Hormone (GH) Therapy: GH is not routinely recommended just because a child is short [11]. Because GH can naturally increase insulin resistance, doctors must carefully weigh the potential for increased height against the risk of worsening blood sugar levels [12].
  • Specialist Evaluation: Before starting any growth treatment, a pediatric endocrinologist will check for a true growth hormone deficiency and monitor growth velocity closely [11].

Supporting Fat Tissue and Metabolism

  • Diet and Lifestyle: A registered dietitian can help create an individualized nutrition plan that manages carbohydrates while ensuring adequate calories and nutrition for growth—which is especially important for lean children. Avoid sugar-sweetened beverages. Regular physical activity improves glucose uptake through multiple pathways, though activity plans must account for any medication-related hypoglycemia risks [13][14].
  • Metreleptin: This is a specialized medication used for some types of lipodystrophy. Metreleptin is established primarily for generalized lipodystrophy in certain jurisdictions. Its use in partial lipodystrophy or SHORT syndrome is not routine, requires severe metabolic disease, and is subject to specialist off-label assessment and regulatory status [10][15].
  • Fat Grafting: For some patients, reconstructive options like autologous fat grafting or fillers may be discussed with a specialist to address facial volume loss, though these are typically considered for cosmetic or functional quality-of-life reasons [16][17].

Ongoing Screenings

Because SHORT syndrome affects multiple systems, “symptom management” means staying ahead of potential complications [4]:

  • Ophthalmology: The ophthalmologist sets the interval for examinations to monitor for glaucoma or cataracts related to the Rieger anomaly. Glaucoma can be asymptomatic [18][19].
  • Dentistry: Early and regular dental care can help manage delays in teething or small teeth [20].
  • Cardiology: Some reports suggest an echocardiogram (heart ultrasound), directed by symptoms, clinical exam, or family history rather than as a universal baseline [4].

Common questions in this guide

How is insulin resistance monitored in SHORT syndrome?
Monitoring usually includes fasting glucose and HbA1c, a longer-term blood-sugar test, with an oral glucose tolerance test in some situations. Testing may become more frequent as a child approaches puberty because insulin resistance can worsen then. The treating endocrinologist should set the schedule.
Does metformin always work for insulin resistance in SHORT syndrome?
No. Some people have better blood-sugar control with metformin, while others have little benefit. A specialist should follow glucose results and side effects to decide whether it is helping.
Can growth hormone treat short stature in SHORT syndrome?
Growth hormone is not routinely used just because a child is short. A pediatric endocrinologist first checks for true growth hormone deficiency and follows growth closely, because growth hormone can worsen insulin resistance. The potential height benefit must be weighed against blood-sugar risks.
What medicines may be used if diabetes develops?
Insulin may be needed, and some people require unusually high doses because of the underlying insulin-signaling problem. Specialists may also consider medicines such as pioglitazone or SGLT2 inhibitors in selected cases, but these uses may be off-label and have important risks. The choice depends on blood-sugar control and the person's overall health.
What screenings are important for someone with SHORT syndrome?
Regular eye examinations can check for glaucoma and cataracts, which may cause no early symptoms. Dental visits help monitor delayed teething and small teeth. A heart ultrasound may be considered based on symptoms, examination findings, or family history rather than as a routine test for everyone.
Can diet and exercise help manage SHORT syndrome?
A registered dietitian can create a nutrition plan that manages carbohydrates while providing enough calories for growth, especially for lean children. Avoiding sugar-sweetened drinks and staying physically active can support blood-sugar control. Activity plans should account for low blood sugar if medicines create that risk.
Is metreleptin routinely used for SHORT syndrome?
Metreleptin is primarily established for some forms of generalized lipodystrophy. It is not routine for SHORT syndrome or partial lipodystrophy and may be considered only by a specialist when metabolic disease is severe and local regulatory rules allow.

Get notified when new evidence is published on Lipodystrophy due to peptidic growth factors deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    New classification and diagnostic criteria for insulin resistance syndrome.

    Ogawa W, Araki E, Ishigaki Y, et al.

    Endocrine journal 2022; (69(2)):107-113 doi:10.1507/endocrj.EJ21-0725.

    PMID: 35110500
  2. 2

    Metformin paradoxically worsens insulin resistance in SHORT syndrome.

    Lewandowski KC, Dąbrowska K, Brzozowska M, et al.

    Diabetology & metabolic syndrome 2019; (11()):81 doi:10.1186/s13098-019-0477-z.

    PMID: 31583022
  3. 3

    Clinical Guidelines for the Diagnosis and Management of Generalized and Partial Lipodystrophies: A Position Statement Endorsed by the Hellenic Endocrine Society.

    Lambadiari V, Bargiota A, Kanaka-Gantenbein C, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(6)):1008-1016 doi:10.1016/j.eprac.2026.02.014.

    PMID: 41713690
  4. 4

    Clinical reappraisal of SHORT syndrome with PIK3R1 mutations: toward recommendation for molecular testing and management.

    Avila M, Dyment DA, Sagen JV, et al.

    Clinical genetics 2016; (89(4)):501-506 doi:10.1111/cge.12688.

    PMID: 26497935
  5. 5

    Insulin resistant diabetes mellitus in SHORT syndrome: case report and literature review.

    Masunaga Y, Fujisawa Y, Muramatsu M, et al.

    Endocrine journal 2021; (68(1)):111-117 doi:10.1507/endocrj.EJ20-0291.

    PMID: 32879144
  6. 6

    SHORT syndrome in two Chinese girls: A case report and review of the literature.

    Zhang Y, Ji B, Li J, et al.

    Molecular genetics & genomic medicine 2020; (8(9)):e1385 doi:10.1002/mgg3.1385.

    PMID: 32602265
  7. 7

    Novel PIK3R1 mutation of SHORT syndrome: A case report with a 6-month follow up.

    Yin X, Liu J, Feng R, et al.

    Journal of diabetes investigation 2021; (12(10)):1919-1922 doi:10.1111/jdi.13549.

    PMID: 33742773
  8. 8

    Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor.

    Hamaguchi T, Hirota Y, Takeuchi T, et al.

    Journal of diabetes investigation 2018; (9(5)):1224-1227 doi:10.1111/jdi.12825.

    PMID: 29476696
  9. 9

    Two Cases of Severe Insulin Resistance in Pregnancy: A New Diagnosis of INSR Variant and a Patient with SHORT Syndrome.

    L'Amie AK, Hall RM, Bate J, et al.

    JCEM case reports 2025; (3(11)):luaf243 doi:10.1210/jcemcr/luaf243.

    PMID: 41140512
  10. 10

    Metreleptin In SHORT Syndrome With Uncontrolled Diabetes.

    Korakas E, Kountouri A, Ikonomidis I, et al.

    JCEM case reports 2025; (3(11)):luaf218 doi:10.1210/jcemcr/luaf218.

    PMID: 41080980
  11. 11

    Management of Short Stature: Use of Growth Hormone in GH-Deficient and non-GH-Deficient Conditions.

    Vyas V, Menon RK

    Indian journal of pediatrics 2021; (88(12)):1203-1208 doi:10.1007/s12098-021-03892-5.

    PMID: 34609657
  12. 12

    Biological effects of recombinant human growth hormone therapy on metabolism in children with growth hormone deficiency: a review.

    Dyrka K, Łachut K, Kolesińska Z, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2025; (38(8)):796-806 doi:10.1515/jpem-2025-0057.

    PMID: 40320660
  13. 13

    Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.

    Vatier C, Vantyghem MC, Storey C, et al.

    Current medical research and opinion 2019; (35(3)):543-552 doi:10.1080/03007995.2018.1533459.

    PMID: 30296183
  14. 14

    The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

    Brown RJ, Araujo-Vilar D, Cheung PT, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.

    PMID: 27710244
  15. 15

    Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy.

    Oral EA, Gorden P, Cochran E, et al.

    Endocrine 2019; (64(3)):500-511 doi:10.1007/s12020-019-01862-8.

    PMID: 30805888
  16. 16

    Barraquer-Simons syndrome: a unique patient's perspective on diagnosis, disease progression and recontouring treatment.

    Heidemann LN, Thomsen JB, Sørensen JA

    BMJ case reports 2016; (2016()).

    PMID: 27402657
  17. 17

    Hyaluronic acid fillers for correcting midface volume deficit in Barraquer-Simons syndrome.

    Afra TP, Vinay K, Razmi T M, et al.

    Journal of cosmetic dermatology 2019; (18(5)):1264-1266 doi:10.1111/jocd.12847.

    PMID: 30604443
  18. 18

    Iris Malformation and Anterior Segment Dysgenesis in Mice and Humans With a Mutation in PI 3-Kinase.

    Solheim MH, Clermont AC, Winnay JN, et al.

    Investigative ophthalmology & visual science 2017; (58(7)):3100-3106 doi:10.1167/iovs.16-21347.

    PMID: 28632845
  19. 19

    Clinical Features, Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome).

    Kaewkrasaesin C, Hwang M, Vasandani C, et al.

    The Journal of clinical endocrinology and metabolism 2025; (111(1)):107-118 doi:10.1210/clinem/dgaf315.

    PMID: 40435301
  20. 20

    SHORT Syndrome: Systematic Appraisal of the Medical and Dental Phenotype.

    Mubeen S, Gibson C, Mubeen R, et al.

    The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association 2022; (59(7)):873-881 doi:10.1177/10556656211026859.

    PMID: 34212753

This page is for informational purposes only and does not constitute medical advice. Decisions about blood-sugar monitoring, medicines, growth hormone, and other SHORT syndrome care should be made with your specialist team.

Guide contents Lipodystrophy due to peptidic growth factors deficiency
Research & Literature
04 Connecting the Clues 06 Ongoing Monitoring and Staying Safe